Kemwell Biopharma

Kemwell Biopharma is a leading biologics CDMO based in Bengaluru, India, offering end-to-end services from cell line and process development to cGMP clinical and commercial manufacturing. Its 15,000-square-meter facility, built with Boehringer Ingelheim, includes 5,000-liter bioreactor capacity and sterile fill-finish for vials and pre-filled syringes; in October 2025, Kemwell completed a US FDA pre-approval inspection for an injectable drug product, reinforcing global quality standards and trusted partnerships dating back to 1980, with a specialization in mammalian cell-based biologics including monoclonal antibodies, complex proteins and biosimilars.